XML 68 R43.htm IDEA: XBRL DOCUMENT v3.22.0.1
Reverse Merger and Contingent Value Rights - Summary of Final Allocation of Purchase Price (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Oct. 05, 2020
Assets:      
Goodwill $ 117 $ 22,441  
Private Chinook      
Assets:      
Cash and cash equivalents     $ 73,159
Marketable securities     98,057
Accounts receivable     1,122
Prepaids and other current assets     1,757
Property and equipment, net     19,039
Operating lease right-of-use assets     53,704
Intangible assets     28,118
IPR&D     39,295
Goodwill     22,441
Restricted cash     1,750
Other assets     295
Total assets acquired     338,737
Liabilities:      
Accounts payable     2,280
Accrued clinical trial and manufacturing expenses     1,632
Accrued compensation     6,854
Accrued and other current liabilities     6,092
Deferred revenue, current     660
Operating lease liability, current     2,230
Existing contingent consideration     1,800
Deferred tax liabilities     18,372
Operating lease liabilities, non-current     36,474
Other non-current liabilities     1,442
Total liabilities assumed     77,836
Net Fair Value     260,901
Private Chinook | Measurement Period Adjustment      
Assets:      
Goodwill     (22,324)
Total assets acquired     (22,324)
Liabilities:      
Accrued and other current liabilities     (690)
Existing contingent consideration     (450)
Deferred tax liabilities     (17,735)
Other non-current liabilities     (753)
Total liabilities assumed     (19,628)
Net Fair Value     (2,696)
Private Chinook | Adjusted Fair Value at Acquisition Date      
Assets:      
Cash and cash equivalents     73,159
Marketable securities     98,057
Accounts receivable     1,122
Prepaids and other current assets     1,757
Property and equipment, net     19,039
Operating lease right-of-use assets     53,704
Intangible assets     28,118
IPR&D     39,295
Goodwill     117
Restricted cash     1,750
Other assets     295
Total assets acquired     316,413
Liabilities:      
Accounts payable     2,280
Accrued clinical trial and manufacturing expenses     1,632
Accrued compensation     6,854
Accrued and other current liabilities     5,402
Deferred revenue, current     660
Operating lease liability, current     2,230
Existing contingent consideration     1,350
Deferred tax liabilities     637
Operating lease liabilities, non-current     36,474
Other non-current liabilities     689
Total liabilities assumed     58,208
Net Fair Value     $ 258,205